A Clinical Study to Assess the Ability of the Adjuvanted Recombinant-Protein COVID-19 Vaccine Candidate to Generate a Strong Booster Response Regardless of Initial Vaccine Platform Received

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 06 Sep 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

31 May 2021 New trial record
27 May 2021 According to a Sanofi media release, following encouraging interim results from the recent Phase 2 study, the companies will also begin clinical studies in the coming weeks (booster study program) complement Phase 3 trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com